Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

ClinicalTrials.gov ID: NCT01252355

Public ClinicalTrials.gov record NCT01252355. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 11:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis Who Are Treated With Interferon-beta

Study identification

NCT ID
NCT01252355
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sanofi
Industry
Enrollment
534 participants

Conditions and interventions

Interventions

  • Interferon-beta (IFN-beta) Drug
  • Placebo (for teriflunomide) Drug
  • Teriflunomide Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 55 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2010
Primary completion
Mar 31, 2013
Completion
Mar 31, 2013
Last update posted
Jun 8, 2014

2011 – 2013

United States locations

U.S. sites
32
U.S. states
21
U.S. cities
29
Facility City State ZIP Site status
Investigational Site Number 840049 Cullman Alabama 35058
Investigational Site Number 840005 Cordova Alaska 38018
Investigational Site Number 840003 Phoenix Arizona 85060
Investigational Site Number 840011 Oceanside California 92056
Investigational Site Number 840036 Fort Collins Colorado 80528
Investigational Site Number 840012 Maitland Florida 32761
Investigational Site Number 840013 Ormond Beach Florida 32174
Investigational Site Number 840055 Pompano Beach Florida 33060
Investigational Site Number 840021 St. Petersburg Florida 33713
Investigational Site Number 840004 Tampa Florida 33609-4052
Investigational Site Number 840047 Tampa Florida 33612
Investigational Site Number 840034 Chicago Illinois 60637
Investigational Site Number 840037 Elk Grove Village Illinois 60007
Investigational Site Number 840033 Louisville Kentucky 40217
Investigational Site Number 840041 Baltimore Maryland 21201
Investigational Site Number 840028 Baltimore Maryland 21287
Investigational Site Number 840016 Clinton Township Michigan 48035
Investigational Site Number 840031 St Louis Missouri 63104
Investigational Site Number 840030 St Louis Missouri 63110
Investigational Site Number 840009 Missoula Montana 59802
Investigational Site Number 840023 Albuquerque New Mexico 87131
Investigational Site Number 840015 New York New York 10029
Investigational Site Number 840027 Charlotte North Carolina 28204
Investigational Site Number 840006 Bismarck North Dakota 58501
Investigational Site Number 840007 Fargo North Dakota 58103
Investigational Site Number 840046 Dayton Ohio 45409
Investigational Site Number 840017 Toledo Ohio 43699
Investigational Site Number 840043 Tulsa Oklahoma 74137
Investigational Site Number 840002 Nashville Tennessee 37232
Investigational Site Number 840040 Round Rock Texas 78681
Investigational Site Number 840020 San Antonio Texas 78231
Investigational Site Number 840032 Vienna Virginia 22182

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 153 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01252355, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 8, 2014 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01252355 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →